Jindong Chen

Dr. Jindong Chen


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
MTMei Tan
Mei Tan
YBYue Bai
Yue Bai
XZXiangmei Zhang
Xiangmei Zhang
JSJian Sun
Jian Sun
CHChengshuang Huang
Chengshuang Huang
YCYan Chen
Yan Chen

2 September 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
JCJindong Chen
Jindong Chen
MZMengmeng Zhou
Mengmeng Zhou
HWHao Wang
Hao Wang
ZZZhihuang Zheng
Zhihuang Zheng
WRWenwen Rong
Wenwen Rong
LZLiang Zhao
Liang Zhao

1 April 2017 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
WZWanqi Zhou
Wanqi Zhou
KTKe Tang
Ke Tang
XCXiaoguang Chen
Xiaoguang Chen
ZFZhiqiang Feng
Zhiqiang Feng
JCJindong Chen
Jindong Chen
While Taxol has been reported to improve the clinical survival of breast cancer patients, subsequently developed drug-resistance of the cancer cells limits its final efficacy and applications. Previous studies suggested that Aurora A is involved in the development of the Taxol-resistance of breast cancer. We established Taxol-resistant breast cancer MCF-7/T cells and xenograft models to explore the role of Aurora A in Taxol resistant ER-positive breast cancer. Compared with their parental MCF-7/C cells, the Taxol-resistant MCF-7/T cells exhibited enhanced colony formation, less cell death and higher invasive ability. The resistant cells presented overexpressed Aurora A, elevated phosphorylated SRC and upregulated Ras/Raf/ERK and Akt/mTOR pathways. Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro. These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol. These results might shed light on the development of strategies to circumvent Taxol-related chemoresistance in breast cancer clinical practice.

9 December 2016 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
JOJian-Jun Ou
Jian-Jun Ou
HLHailong Lyu
Hailong Lyu
MHMaorong Hu
Maorong Hu
JLJun Li
Jun Li
Wenbin GuoWenbin Guo
Wenbin Guo
JZJingping Zhao
Jingping Zhao

2 January 2019 in Hemoglobin
Verified
Journal Article
Closed access
QSQiong Su
Qiong Su
SCShiping Chen
Shiping Chen
LWLiusong Wu
Liusong Wu
RTRunmei Tian
Runmei Tian
XYXiaoqin Yang
Xiaoqin Yang
JCJindong Chen
Jindong Chen
Hemoglobinopathies are caused by genetic defects on the globin genes. To date, more than 900 β-globin variants have been recorded worldwide. These gene alterations often cause either a decrease in β-globin synthesis or completely block synthesis, leading to a hemoglobinopathy. While most of these causative mutations are inherited, de novo mutations are quite rare. Here, we investigated three hemoglobinopathy cases. These patients developed severe hemolytic anemia at 3-5 months of age and were transfusion-dependent. In patient 1, a novel β variant, Hb Zunyi [β147(HC3)Stop→Gln; HBB: c.442T>C] was identified. This de novo mutation results in a stop codon substitution to a glutamine residue at codon 147 of the β-globin gene, and leads to severe thalassemia. In patient 2, we discovered the rare Hb Southampton mutation [β106(G8)Leu→Pro; HBB: c.320T>C], while in patient 3, the rare Hb Alesha mutation [β67(E11)Val→Met (GTG>ATG); HBB: c.202G>A] was detected. The identification of the novel β variant, Hb Zunyi, has added to the human globin database and will shed light on future diagnosis of hemoglobinopathy/thalassemia and genetic counseling.

27 January 2020 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
QZQiurong Zhao
Qiurong Zhao
MWMingsong Wu
Mingsong Wu
XZXiang Zheng
Xiang Zheng
LYLei Yang
Lei Yang
ZZZhimin Zhang
Zhimin Zhang
JCJindong Chen
Jindong Chen
Background: Brefeldin A (BFA) has been known to induce endoplasmic reticulum stress (ERS) and Golgi body stress in cancer cells. ERGIC3 (endoplasmic reticulum-Golgi intermediate compartment 3) is a type II transmembrane protein located in the endoplasmic reticulum and Golgi body. ERGIC3 over-expression is frequently observed in cancer cells. Objective: In this study, we aim to explore whether BFA administered concurrently with ERGIC3 silencing would work additively or synergistically inhibit cancer cell growth. Methods: ERGIC3-siRNA was used to knock-down the expression of ERGIC3 and BFA was used to induce ERS in lung cancer cell lines GLC-82 and A549. Q-RT-PCR and Western Blot analysis were used to detect the expression of ERGIC3 and downstream molecules. GraphPad Prism 6 was used to quantify the data. Results: We demonstrated that silencing of ERGIC3 via siRNA effectively led to down-regulation of ERGIC3 at both mRNA and protein levels in GLC-82 and A549 cells. While BFA or ERGIC3- silencing alone could induce ERS and inhibit cell growth, the combination treatment of lung cancer cells with ERGIC3-silencing and BFA was able to additively enhance the inhibition effects of cell growth through up-regulation of GRP78 resulting in cell cycle arrest. Conclusion: ERGIC3 silencing in combination with BFA treatment could additively inhibit lung cancer cell growth. This finding might shed a light on new adjuvant therapy for lung adenocarcinoma.